drugset / Trial / NCT00934466

Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)

NCT00934466

Phase 1 Completed 15 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindDiagnostic

Summary

This study will assess transcranial magnetic stimulation (TMS) as a biomarker and characterize TMS readouts of the activity of MK2637 and dextromethorphan. Resting quantitative electroencephalography(qEEG) readouts are also characterized with MK2637 and dextromethorphan.

Timeline

Start
2009-07
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dextromethorphan Unknown 110 mg
Comparator Dextromethorphan Unknown 220 mg
Subject MK2637 Unknown 50 mg
Subject MK2637 Unknown 120 mg

Indications